These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23529925)

  • 21. Use of metformin in pediatric age.
    Brufani C; Fintini D; Nobili V; Patera PI; Cappa M; Brufani M
    Pediatr Diabetes; 2011 Sep; 12(6):580-8. PubMed ID: 21366813
    [No Abstract]   [Full Text] [Related]  

  • 22. Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity.
    Hoppin AG; Katz ES; Kaplan LM; Lauwers GY
    N Engl J Med; 2006 Oct; 355(15):1593-602. PubMed ID: 17035653
    [No Abstract]   [Full Text] [Related]  

  • 23. [Liraglutide in the treatment of diabetes type 2].
    Novak B; Metelko Z
    Lijec Vjesn; 2011; 133(7-8):269-76. PubMed ID: 22165195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 25. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
    Giannoukakis N
    Curr Opin Investig Drugs; 2007 Oct; 8(10):842-8. PubMed ID: 17907061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicinal chemistry of glucagon-like peptide receptor agonists.
    Jones LH; Price DA
    Prog Med Chem; 2013; 52():45-96. PubMed ID: 23384666
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of metabolic syndrome in children and adolescents.
    Pacifico L; Anania C; Martino F; Poggiogalle E; Chiarelli F; Arca M; Chiesa C
    Nutr Metab Cardiovasc Dis; 2011 Jun; 21(6):455-66. PubMed ID: 21565479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antidiabetics and the incretin system].
    Høibraaten E; Folkersen J
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1985. PubMed ID: 18787580
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetes medications and cancer: a way out of uncertainty.
    Gallo M; Esposito K; Giugliano D
    Diabetes Res Clin Pract; 2012 Aug; 97(2):175-7. PubMed ID: 22560795
    [No Abstract]   [Full Text] [Related]  

  • 31. Metformin: the hidden chronicles of a magic drug.
    Mahmood K; Naeem M; Rahimnajjad NA
    Eur J Intern Med; 2013 Jan; 24(1):20-6. PubMed ID: 23177353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [DPP-4 inhibitors, GLP-1 receptor agonists].
    Hamasaki A; Inagaki N
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():654-61. PubMed ID: 21766677
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
    Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
    Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 35. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 36. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characteristics of the therapy of patients with type II diabetes mellitus and metabolic syndrome].
    Bodnar PM; Kononenko LO
    Lik Sprava; 2000; (7-8):92-4. PubMed ID: 16786661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin therapy for diabetes in Prader-Willi syndrome.
    Chan NN; Feher MD; Bridges NA
    J R Soc Med; 1998 Nov; 91(11):598. PubMed ID: 10325882
    [No Abstract]   [Full Text] [Related]  

  • 40. The 'worried-well', insulin resistance and metformin therapy.
    Distiller LA; Landau S; Joffe B; Kramer B; Blacking L
    S Afr Med J; 2005 Jun; 95(6):366. PubMed ID: 16100876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.